Monte Rosa Therapeutics, Inc.

NasdaqGS:GLUE Stock Report

Market Cap: US$1.5b

Monte Rosa Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:GLUE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
14 Apr 26SellUS$141,125Markus WarmuthIndividual8,000US$17.64
09 Apr 26SellUS$103,413Philip NicksonIndividual5,845US$17.69
04 Mar 26SellUS$2,496Edmund DunnIndividual139US$17.96
23 Feb 26SellUS$179,161Filip JankuIndividual9,189US$19.50
07 Jan 26SellUS$13,753,881Versant Venture Management, LLCCompany597,931US$23.33
05 Jan 26SellUS$15,762Edmund DunnIndividual1,039US$15.17
05 Jan 26SellUS$47,861Philip NicksonIndividual3,155US$15.17
05 Jan 26SellUS$47,861Sharon TownsonIndividual3,155US$15.17
05 Jan 26SellUS$39,882Jennifer ChampouxIndividual2,629US$15.17
05 Jan 26SellUS$47,861Filip JankuIndividual3,155US$15.17
05 Jan 26SellUS$153,748Markus WarmuthIndividual10,135US$15.17

Insider Trading Volume

Insider Buying: GLUE insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of GLUE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders467,6590.486%
VC/PE Firms12,314,44912.8%
Hedge Funds18,696,69619.4%
Institutions64,778,37067.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 37.3%.

Top Shareholders

Top 25 shareholders own 91.08% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.11%
New Enterprise Associates, Inc.
7,692,298US$140.8m0%9.37%
7.95%
T. Rowe Price Group, Inc.
6,720,188US$123.0m31.3%0.01%
6.7%
Dimension Capital Partners, LLC
5,663,265US$103.7m0%no data
6.67%
BlackRock, Inc.
5,637,684US$103.2m34.8%no data
5.47%
TCG Crossover Management, LLC
4,622,151US$84.6m0%2.17%
5.28%
BVF Partners L.P.
4,460,886US$81.7m16.3%2.18%
5.14%
Baker Bros. Advisors LP
4,345,736US$79.6m0%0.41%
5%
Suvretta Capital Management, LLC
4,226,809US$77.4m25.8%1.85%
4.27%
Vestal Point Capital, LP
3,603,465US$66.0m365%1.8%
3.97%
State Street Global Advisors, Inc.
3,353,980US$61.4m59.2%no data
3.8%
Braidwell LP
3,206,574US$58.7m238%2.0%
3.77%
Versant Venture Management, LLC
3,180,780US$58.2m-27.4%40.34%
3.67%
Vanguard Capital Management, LLC
3,100,245US$56.8m0%no data
3.33%
American Century Investment Management Inc
2,809,647US$51.4m111%0.02%
2.37%
Silverarc Capital Management, LLC
2,002,040US$36.7m94.6%4.64%
1.84%
Aisling Capital Management LP
1,555,664US$28.5m5.66%6.41%
1.82%
Geode Capital Management, LLC
1,540,812US$28.2m27.9%no data
1.7%
Marshall Wace LLP
1,433,152US$26.2m259%0.03%
1.67%
HBM Partners Ltd.
1,407,040US$25.8m0%2.26%
1.48%
Bellevue Asset Management AG
1,250,000US$22.9m0%0.44%
1.39%
MPM BioImpact LLC
1,176,928US$21.5m0.3%1.44%
1.23%
Dimensional Fund Advisors LP
1,041,372US$19.1m83.2%no data
1.21%
FMR LLC
1,024,304US$18.8m-21.2%no data
1.18%
Frazier Life Sciences Management, LP
1,000,000US$18.3m0%0.45%
1.05%
The Goldman Sachs Group, Inc.
891,158US$16.3m355%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/22 07:00
End of Day Share Price 2026/06/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monte Rosa Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Michael SchmidtGuggenheim Securities, LLC
Dingding ShiJefferies LLC